Background: Electroconvulsive therapy (ECT) constitutes one of the most effective
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INTRODUCTION
Electroconvulsive therapy (ECT) constitutes a rapidly acting and highly potent -though clearly unspecific -treatment option in psychiatry, where a generalized seizure is induced under controlled circumstances and expected to alleviate mental symptoms [1] . The potential of ECT is very high with response-rates up to 80% in the main indication major depression (major depressive disorder, MDD) [2, 3] . Even when it comes to treatment-resistant conditions (treatment-resistant depression, TRD) [4, 5] remission rates between 40 and 50% can be expected after ECT [6] . Interestingly, in spite of its common use and well-documented efficacy in MDD since over 80 years [7] , its complex mechanisms of action are still relatively unclear and no consensus has been reached in this concern. Several lines of evidence have been pursued to clarify the issue, but were only partially successful in detecting neurobiological markers that correlate with treatment effects of ECT [8] [9] [10] . In this context, special attention has been paid to the neuroendocrine system, by investigating functional changes of the hypothalamic-pituitary-adrenal (HPA) axis after ECT [11] , and adult neurogenesis, by assessing levels of brain-derived-neurotrophic factor (BDNF) [12] during a course of ECT as well as gray matter volume changes after treatment, particularly in the hippocampus region [13, 14] . Thirdly and most prominently, effects of ECT on brain function in terms of glucose metabolism and cerebral blood flow as surrogate markers of neuronal activity as well as specific neurotransmitter systems using molecular neuroimaging techniques have been intensively studied [8, 15] . However, a differentiation between imminent seizure-associated alterations and actual treatment-related changes could not be ascertained in these investigations [12, 13, 16] .
Regarding the impact of ECT on specific neurotransmitter systems, the wealth of data retrieved from preclinical research has led to the common view that ECT enhances monoaminergic neurotransmission, more specifically dopaminergic, noradrenergic and serotonergic signaling, and that this boost of monoamines explains the powerful effects of M A N U S C R I P T
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ECT in treating severe mental states [17] . However, evidence in humans regarding the effects of ECT on neurotransmission is very limited and lacks replication. Only three studies have hitherto directly investigated this relationship in depressed patients by means of positron emission tomography (PET) and were able to report effects. We previously showed that ECT leads to a widespread reduction of serotonin-1A receptor density in the cortex and the hippocampus-amygdala complex [18] , unlike in rodents but similar to observations reported under treatment with selective serotonin-reuptake inhibitors (SSRI) [19] . Similarly, Yatham et al. demonstrated that ECT goes along with a reduction of cortical serotonin-2A receptors in depressed patients [20] , which is equally similar to antidepressants and unlike the pattern shown in animal studies. Lastly, ECT was shown to be accompanied by a reduction of dopamine D2 receptor density in the rostral anterior cingulate cortex [21] .
One central monoaminergic molecule is the monoamine oxidase A (MAO-A). It is the key enzyme responsible for the degradation of serotonin, norepinephrine and dopamine and its adequate function specifically maintains the homeostasis of cerebral serotonin concentrations in humans [22, 23] . MAO inhibitors (MAOI) represent an important element in the therapeutic armamentarium of psychiatrists, notably the irreversible MAOI such as tranylcypromine were shown to be highly effective in treatment-resistant depression and atypical depression [24, 25] . Due to less dietary restrictions and interactions with other serotonergic agents, reversible MAOI such as moclobemide are more commonly in use in clinical practice and studies support this class of antidepressants of being equally safe and tolerable as SSRIs [26, 27] . In accordance with the monoamine hypothesis of depression [28] , Meyer et al. showed that elevated cerebral MAO-A density measured using PET represents one of the main serotonin-lowering processes in medication-free depressed patients and may even constitute a trait marker of major depression [29, 30] . In fact, studies find that MAO-A levels were 34-40% higher in MDD than in healthy controls [30, 31] . This relative difference constitutes one of the largest discrepancies between depressed and healthy subjects in terms of a molecular endophenotype of MDD. A significant elevation of M A N U S C R I P T
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6 MAO-A was also found in the hypothalamic regions in postmortem brains of suicide victims [32] . Furthermore, increased MAO-A expression has been associated with the early postpartum period [33] , perimenopause [34] , and severe, atypical depression [35] . Brain MAO-A availability was shown to be affected by the reversible MAO-A inhibitor moclobemide and a MAO-A occupancy level of 74% was proposed as a desirable threshold level to have therapeutic impact in MDD [36, 37] .
At present, it is a challenge to reliably assess the direct or indirect impact of antidepressant treatments on MAO-A in depression. As a logical consequence the present study aimed at investigating the availability of MAO-A in its role as major monoamine-regulatory enzyme with respect to the most effective therapeutic tool currently available in the treatment of depression, namely ECT. The development of accurate neuroimaging techniques and specific radioligands has broadened the possibilities of analyzing the major components of the monoaminergic system. As the current state-of-the-art investigational tool for examining central MAO-A in humans, [ Here, we determined MAO-A V T in depressed patients before and after a course of ECT compared to healthy subjects using PET and the tracer [ 11 C]harmine in order to expand our previous findings regarding the effect of ECT on serotonin-1A receptor levels [18] and provide a further coherent explanatory model for ECT's mechanism of action in MDD.
MATERIAL and METHODS
Subjects and study design
Two groups of subjects were enrolled in the study: 16 inpatients with severe unipolar depression (mean age ± SD = 45.94 ± 9.68 years, 12 women) and 16 
was assessed by interviewing the patients and based on the previously recorded medical history. Depressed participants had to fulfill inclusion criteria for ECT, including an internistic and anaesthesiological approval (electrocardiography, thoracic X-ray, laboratory measurements, physical examination). Exclusion criteria were concomitant major neurologic illness, current substance abuse (including nicotine abuse as cigarette smoking has been associated with lower MAO-A levels) [33] , schizophrenia or schizoaffective disorder and previous ECT. Current substance abuse was ruled out using the SCID and a routine urine drug screening including cotinine. A causal relationship of mood disturbances and general medical conditions was further ruled out by routine laboratory measurements (electrolyte levels, complete blood cell count, thyroid function and virology). Treatment with drugs targeting directly the MAO-A, such as moclobemide, was not admitted and had to be discontinued at least for six month prior inclusion. For ethical reasons, antidepressant medication and augmentation therapy with antipsychotics was continued and had to be left unchanged during ECT and study participation (see Table A .1 for an overview of psychotropic medication of the sample). Mood-stabilizers were similarly tolerated; however, dosages of drugs with anticonvulsant properties and lithium had to be reduced prior to study enrollment to not compromise ECT and prevent delirium [41, 42] . All drugs had to be in steady state for at least ten days before inclusion, apart from benzodiazepines that were tolerated in varying dosage and administered on demand given the clinical indication (see Table A .1). From the initially screened 21 patients, four patients were screening failures (due to refusal of arterial blood sampling and refusal of ECT, multi-morbidity, previous treatment with ECT), while one patient dropped out after the first PET measurement because of discontinuation of inpatient therapy before start of the first ECT session. Therefore, 16
patients were enrolled in the final analysis.
The age-and sex-matched control subjects were in part newly recruited for the study by local advertisement. Seven healthy subjects with compatible inclusion criteria had participated in an earlier PET study using [ have been shown previously by our group [43] . Subjects had to be physically healthy, nonsmoking and without any history of previous mental disorder or treatment with psychotropic medication. General health was ensured by physical examination, electrocardiography and routine laboratory measurements.
All subjects provided written informed consent after detailed explanation of the study by an experienced psychiatrist. The participants were reimbursed for participation. The study was approved by the Ethics Committee of the Medical University of Vienna and the General Hospital of Vienna.
Electroconvulsive therapy (ECT)
Electroconvulsive therapy was conducted using the Thymatron® System IV device (Somatics, LLC., Lake Bluff, Illinois, USA) according to the standard operating procedures of the Department of Psychiatry and Psychotherapy, based on international guidelines and consensus statements for ECT treatment [3, [44] [45] [46] . ECT was carried out twice or three times weekly under anesthesia with methohexital and administration of the muscle relaxant succinylcholine. The stimulation method was restricted to a unilateral electrode placement at the right frontotemporal position and a brief pulse width of 0.50 ms. The exclusivity of a unilateral treatment not only reduces the risk for cognitive side effects [47] but also the number of confounding variables potentially creating a greater MAO-A variability in the sample. If a switch to a bilateral treatment approach was indicated due to insufficient response, low ictal quality or acuity of the mental state, the patient had to be withdrawn from the study. Seizure duration was determined routinely by electroencephalography (EEG).
Furthermore, an electromyogram (EMG) was recorded on one forearm to monitor the M A N U S C R I P T Changes in depressive symptoms after ECT were assessed according to the HAM-D score.
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Positron emission tomography (PET)
Synthesis and quality control of [ [38] . A cross-calibrated gamma counter was used to calculate M A N U S C R I P T
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11 radioactivity concentrations in plasma. Radioactive metabolites of the tracer were determined using high-performance liquid chromatography (HPLC) [52] .
Magnetic Resonance Imaging (MRI)
For co-registration of PET data in SPM (Wellcome Trust Centre 
Data preprocessing and monoamine oxidase A quantification
Quantification was carried out using PMOD 3.509 (PMOD Technologies Ltd., Zurich, Switzerland; www.pmod.com). By multiplication of whole blood activity, plasma-to-whole blood ratio and the fraction of intact radioligand in the plasma, the final arterial input function (AIF) was obtained. MAO-A volume of distribution V T was quantified by using the constrained two-tissue compartment model (2TCM). To assure a stable outcome, the fit of K 1 /k 2 was carried out by coupling the frontal, temporal, parietal, occipital and cingulate cortex, amygdala and hippocampal complex, insula, striatum, thalamus, midbrain and the cerebellar gray matter [38] . Regional V T were delineated by regions-of-interest (ROIs) from the AAL atlas [53, 54] , in combination with a delineation of the midbrain in standard space, and fitted along with the kinetic modelling procedure.
The primary endpoint of the analyses was MAO-A V T in 27 ROIs (13 homologous areas in both hemispheres and one central structure), namely the superior, middle and inferior frontal gyrus, superior, middle and inferior temporal gyrus, anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), hippocampus, amygdala, caudate, putamen, thalamus, separated for both hemispheres, and midbrain (AAL atlas) [53] . ROI-selection was based on previous M A N U S C R I P T
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12 findings in the context of MAO-A expression and depression as well as our previous PET study investigating the serotonin-1A receptor [18, 29, 30] .
Statistical analysis
IBM SPSS Statistics 23 was used for statistical analysis.
First, we performed a linear mixed model analysis to assess the effects of ECT on regional MAO-A V T using time point (PET1, PET2 and PET3), ROI and hemisphere as fixed factors and subjects as the random factor. Of note, the factor hemisphere was introduced in the Secondly, we performed a linear mixed model analysis to assess baseline differences in regional MAO-A V T between MDD subjects (PET1) and healthy controls using group as between-subjects factor, ROI and hemisphere as repeated factors and subjects as the random factor.
To assess treatment response to ECT, a paired t-test was performed contrasting pretreatment and post-treatment HAMD scores in the patients' group.
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The significance level was set at 0.05 in all analyses. Further exploratory evaluations of data are presented at an uncorrected significance level.
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RESULTS
There was no significant difference in depression severity between screening visit and the visit before the 1 st ECT session (t=1.44, p=0.16, see Table 1 ). ECT led to a significant reduction of HAM-D scores in TRD patients (t=12, p<0.001, see Table 1 ), corresponding to a response rate of 87.5%. Of 16 treated patients, 14 were considered as treatment responders,
given a reduction of the baseline HAM-D by ≥50%. 10 (62.5%) of the latter were even considered as remitters with HAM-D≤7 after ECT. Two patients failed to respond to ECT.
Patients were treated with an average of 8.56 ± 0.96 (mean ± SD) right-unilateral ECT sessions and showed mean seizure duration of 40.42 ± 10.79 sec. (see Table 1 ).
Linear mixed models analysis assessing the effect of ECT on MAO-A V T in depressed An exploratory evaluation of ECT-induced MAO-A V T changes for each ROI separately revealed no significant main effect of time. Furthermore, post-hoc comparisons showed no significant difference, though a numerical reduction of V T after ECT could be observed in each of the ROIs investigated (see Table 2 and Figure 3 ). Repeating the analysis only including women (four men excluded from the analysis) revealed a significant reduction of MAO-A V T after ECT in the superior temporal gyrus (p=0.045) and a trend for MAO-A V T reductions in the ACC, PCC and amygdala (all p<0.09, uncorrected). Excluding the two nonresponders or excluding the four patients with additional psychotic symptoms had no effect on our findings, respectively. Moreover, testing for an effect of age, age at disease onset, illness and mean seizure duration had no influence on the non-significance of our results. showing an increased MAO-A V T in TRD women compared to healthy controls in nearly every ROI investigated (see Table B .1, all p values uncorrected). Finally excluding the four patients suffering from psychotic depression from the analysis had no effect on our findings.
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The main finding of this longitudinal PET study is that MAO-A distribution volume assessed over 27 regions of interest was found to be unaffected by a series of minimum eight unilateral ECT sessions. More specifically, though MAO-A V T was shown to be significantly reduced after ECT in depressed patients (linear mixed model), the small effect size of -3.8% was shown to lie in the range of the determined test-retest variability in this sample (3.1%). This was further underlined by a direct comparison (paired t-test) of change scores of MAO-A V T between PET1 and PET2 (both baseline scans) and those between PET2 and PET3 which was not significant. A reduction of MAO-A V T of 3-4% is unlikely to have clinically meaningful effects given that MAO-A occupancies range between 74-87% for moclobemide at different dosages and around 87% for phenelzine [37] . Therefore, our finding does not effectively an increased MAO-A V T in MDD patients [29, 30] , one might as well have expected a downregulation, albeit indirectly triggered, in line with a "normalization" of monoaminergic neurotransmission following response to ECT. Regarding the latter, our negative finding is in accordance with a PET study showing that MAO-A V T remained unchanged after a six-week trial with SSRI implying that the antidepressant-treated state does not equal the healthy state on a molecular level even when remission can be achieved [29] . Given the higher potency [55] , broader spectrum of effects and diagnostic-unspecificity of ECT compared to SSRI [56] , an effect on MAO-A levels could still have been expected. Also, as ECT was shown to affect serotonergic neurotransmission on multiple levels with previously published reports showing M A N U S C R I P T
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18 changes in serotonin-1A and 2A receptor density following a course of ECT [18, 57] , a relevant change in MAO-A expression after treatment might have seemed intuitive.
Compared to previously published neuroimaging studies in the field [29, 30, [33] [34] [35] [36] , the depressed sample included in the present study was medicated. We must assume that the psychopharmacological medication administered to the patients in this sample acting on different molecular targets may explain the fact that we could not reliably validate the previously reported higher MAO-A V T in medication-free, severely depressed patients compared to heathy subjects [30, 35] . These effects might be masked by medication-induced changes or interactions in our sample, considering that the potency of most of the drugs administered continuously during study participation (see Table A .1) in inhibiting MAO-A (IC 50 ) is not known. Also, illness severity seems to be a crucial factor regarding the reported elevation of cerebral MAO-A density which could not be observed in previously investigated mildly to moderately depressed patients, even when unmedicated [35, 36] . Here, we included only patients with a HAMD 17 greater than 23 referred to the department for the administration of ECT and fulfilling criteria for treatment-resistance [3, 40, 43] . TRD is associated with distinct sociodemographic, clinical and biological risk factors that are not necessarily associated with non-treatment-resistant depression [4, 5, [58] [59] [60] [61] which might equally contribute to the fact that we could not ascertain the findings published by Meyer et al. [30] .
Elevated MAO-A might indeed represent a trait marker of depression or at least increase the vulnerability to developing the disorder; however, based on the current evidence in this concern, no definitive conclusions can be drawn regarding MAO-A expression neither in TRD nor under long-term antidepressant treatment. Another relevant factor is that out of twelve women included in this study nine were over 45 years of age at study inclusion. MAO-A V T was reported to be elevated by 34% in perimenopausal women compared with reproductive age and by 16% compared with menopause [34] , an effect similar to the effect of MDD on MAO-A V T [30] and therefore potentially biasing our findings. Though the exclusion of men did not have an impact on the non-significance of our longitudinal findings, the exploratory M A N U S C R I P T
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analysis performed on the baseline data (TRD vs. healthy women) showed elevated MAO-A V T in nearly every ROI investigated in patients, conforming with previous data (see Table   B .1) [30] . We cannot rule out that changes of MAO-A V T associated with peri-and postmenopause in our sample not only mask TRD-induced alterations of MAO-A density but also possible ECT-induced effects. However, as age-and sex-matched controls were included in our analysis, we consider these effects to be corrected for.
Though MAO-A density was shown to be unaffected by clinical response to short-term use of SSRI (six weeks) in previously untreated depressed patients [29] , we must assume -as stated before -a relevant influence of long-term antidepressant treatment on MAO-A expression that potentially influences our findings. To minimize this bias, psychopharmacological treatment remained unchanged during study participation with the exception of benzodiazepines. Nevertheless, from a clinician's point of view and for ethical reasons, a discontinuation of treatment was inacceptable in this severely-ill TRD sample.
Moreover, this sample rather reflects the real-world clinical situation that physicians are facing when dealing with treatment-resistant patients. In fact, in clinical practice antidepressant treatment is commonly continued during ECT (apart from punctual discontinuation before an ECT session to reduce risk for hypertension or delirium for noradrenergic agents or lithium, respectively) [41, 42] as positive synergistic effects of both treatment options are expected [62, 63] , though this approach is not necessarily supported by controlled trials [64] . The present findings indirectly support the continuation of pharmacological antidepressant treatment after a course of ECT, which is generally performed to prevent relapse [65] , by providing a rational for the use MAOI as an independent treatment option after completion of ECT as both seem to have similar distinct mechanisms of action and thereby bear synergistic potential in terms of antidepressant potency. Interestingly, both therapeutic options are usually considered when it comes to treatment-resistant conditions in MDD [26, 66] . However, clinical studies are needed to substantiate this assumption as the present study was not designed to test this hypothesis.
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The theory that the combination of MAOI and ECT is associated with a higher cardiovascular risk was not supported by the literature [67, 68] .
Several limitations to the study must be addressed. We used only unilateral ECT in this investigation. This approach was chosen in order to unify our sample and limit cognitive side effects potentially associated with ECT treatment and changes in MAO-A expression.
Bilateral ECT often considered being more effective in depression [69] , we cannot extrapolate from our present findings to the effects of bilateral ECT on MAO-A V T . However, the factor hemisphere being incorporated in our statistical model, we could not detect lateralized effects of ECT on MAO-A V T . The response rates of 87.5% achieved in our sample align with those commonly reported in the literature and support critical voices that consider high-dosage unilateral ECT as similarly effective as bilateral treatment [2] . Further, changes in menstrual cycle length (perimenopause) and menopause were not specifically assessed in our study. Women in this age class are at high risk for major depression [70, 71] and therefore likely to be referred to a specific antidepressant treatment including ECT.
Lastly, no psychometric scales apart from the HAMD were recorded in this study. Evidence points towards an association of MAO-A density with atypical depression [35] , REM sleep deprivation which is closely associated with MDD [72] as well as glucocorticoid exposure (acute and chronic stress) [73, 74] . In fact, the inpatient stay itself might impact on MAO-A levels via changes in experienced stress levels and associated sleep pattern deviations, thereby influencing test-retest variability of MAO-A V T (-3.1%). Though depression severity remained unchanged in TRD patients before the start of ECT, we recommend future studies focused on MAO-A to specifically consider these factors.
In summary, we were able to detect a significant reduction of MAO-A V T assessed over 27
regions of interest involved in the pathophysiology of depression after a course of ECT [30] .
However, the effect size was small and similar to the test-retest variability determined in this study. We are led to conclude that MAO-A does not significantly contribute to the mechanism M A N U S C R I P T
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of action of ECT in treating depression. In the present analysis, MAO-A V T of medicated TRD patients did not significantly differ from healthy controls. As ECT was shown to influence other major players involved in the pathophysiology of MDD, such as the serotonin-1A [18] and serotonin-2A receptor [57] , further studies in this research direction seem necessary to complete the picture of ECT's effect on serotonergic neurotransmission. Moreover, our findings provide a theoretical basis for the use of MAOI in treatment-resistant patients after ECT, as both treatment options exhibit distinct mechanisms of action. Demographic data of patients suffering from treatment-resistant depression (TRD) and healthy control (HC) subjects are summarized. F = female, M = male, Min = minimum, max = maximum, SD = standard deviation, ECT = electroconvulsive therapy, HAMD = Hamilton Depression Rating Scale, mC = millicoulomb, PET, positron emission tomography. Mean regional MAO V T (and standard error, SE) of patients suffering from treatment-resistant depression (TRD) at PET1 (baseline), PET2 (before start of electroconvulsive therapy, to assess test-retest reliability between both baseline scans) and PET3 (after a series of eight to ten electroconvulsive therapies) and sex-and age-matched healthy controls (HC, 
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HIGHLIGHTS
• The strong therapeutic efficacy of electroconvulsive therapy in major depression seems to be mediated by changes in neurotransmitter systems, particularly the serotonergic system. The monoamine oxidase A (MAO-A) is the major monoamine-degrading enzyme in the human brain and thus responsible for maintaining the homeostasis of serotonergic turnover.
• The effect of right-unilateral electroconvulsive therapy on MAO-A volume of distribution is investigated using positron emission tomography and the highly-selective MAO-A radioligand [
11 C]harmine in 16 medicated patients suffering from treatment-resistant depression and compared to healthy subjects.
• MAO-A expression is significantly reduced following ECT compared to baseline (-3.8%) in 27 a priori defined regions of interest that were previously shown to exhibit a higher MAO-A density in depressed subjects than controls. However, this reduction lies in the range of testretest variability (3.1%) and hence may not constitute a clinically-relevant mechanism of action of electroconvulsive therapy.
• MAO-A expression is similar in medicated depressed patients and age-and sex-matched healthy subjects indicating an influence of continuous antidepressant medication on MAO-A, as the enzyme was previously shown to represent a trait-marker of depression with higher levels in affected individuals.
